Breast Cancer
Read Time: 13 mins

Endocrine Therapy-related Endocrinopathies—Biology, Prevalence, and Implications for the Management of Breast Cancer

Copy Link
Published Online: Feb 16th 2020 Oncology & Hematology Review (US). 2020;16(1):17–22 DOI:
Authors: Kristy A Brown, Eleni Andreopoulou, Panagiota Andreopoulou
Quick Links:
Article Information

Nearly 270,000 new breast cancer cases are predicted to be diagnosed in the USA in 2019 with more than 70% being estrogen receptor positive and treated using endocrine therapy. The suppression of estrogen biosynthesis or action via the use of ovarian suppression, aromatase inhibitors and selective estrogen receptor modulators/degraders, respectively, is effective in approximately 70% of women. The systemic inhibition of estrogen during breast cancer treatment is also associated with side effects due to the important endocrine functions of this steroid hormone, including its role in the maintenance of energy homeostasis and bone health. The current work will present perspectives of the impact of endocrine therapy from the point of view of breast medical oncology, endocrinology, and basic science.


Endocrine therapy, breast cancer, endocrinopathies, metabolism, bone health


Breast cancer is one of the most common types of cancers and will affect one in eight women in their lifetime.1 With the majority of breast cancers being estrogen receptor (ER)-positive, a large proportion of women will receive adjuvant endocrine therapy to prevent recurrence. Endocrine therapy represents a highly effective therapeutic option, with 5-year survival rates over 90%.2 However, despite being effective at halting the growth of breast tumors, systemic suppression of estrogen biosynthesis/action is also associated with important side effects. Endocrinopathies associated with endocrine therapy use in breast cancer are an issue of significant magnitude and a number of recent studies have highlighted the endocrine and metabolic complications that occur as a result of treatment.3 More specifically, an association has been observed for risk of diabetes mellitus and osteoporosis, also common in the general population, and especially in postmenopausal and aging women. Treatment may therefore compound the effects of aging and have long-term implications for years after treatment has ended.

What is endocrine therapy?

There are currently three pharmacological classes of endocrine therapy used for the treatment of breast cancer: aromatase inhibitors, selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs). Aromatase inhibitors, steroidal and non-steroidal, bind to the aromatase enzyme and inhibit the conversion of androgens into estrogens. Their use is largely limited to postmenopausal women due to ineffective suppression of ovarian estrogen biosynthesis in premenopausal women.4 Nevertheless, studies have demonstrated potential benefit of combining aromatase inhibitors with surgical or chemical ovarian ablation in premenopausal women.4 After menopause, the adipose tissue, including that of the breast, is the main site of estrogen production.5,6 Estrogens are also synthesized in the bone, joints, and brain.5 In these women, aromatase inhibitors are effective at suppressing aromatase throughout the body, thus profoundly decreasing estrogen levels both locally and systemically.7,8 SERMs, e.g. tamoxifen, bind to the ER and block binding of estrogens. SERMs can also act as ER agonists, altering receptor/co-regulators interactions.8 As such, SERMs have been shown to affect gene expression and cell biology differently in different tissues. For example, despite being effective at stopping the growth of breast cancer cells, tamoxifen can also stimulate the proliferation of endometrial cells, leading to uterine polyps and in some cases, endometrial hyperplasia and cancer.9 SERDs, e.g. fulvestrant, are pure anti-estrogens and binding to the ER leads to its degradation. Therefore, ligand-independent effects of ER, seen in some cases of endocrine therapy resistance, are not observed with the use of SERDs.10

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most prevalent of breast cancer subtypes and accounts for approximately 70% of all breast cancers.11 Approximately 90% of patients with breast cancer are diagnosed at an early stage and these patients are treated on a curative intent with local therapy and adjuvant systemic therapy based on estimated individual risk for relapse and predicted sensitivity to available systemic therapies.12–15 Modern endocrine therapy is very effective as treatment for ER-positive breast cancer. In the early stage setting, adjuvant endocrine therapy given for 5 years after primary surgery substantially delays local and distant relapse and prolongs overall survival.16 Responsiveness to endocrine therapy, for the most part, is dependent on the presence of a functional ER, which is detected in approximately 70–80% of primary breast cancers and regulates endocrine-dependent growth in these tumors. Endocrine manipulation is achieved either at a cellular level by using anti-estrogens, such is tamoxifen, to compete for ER in the breast tumor, or systemically, by lowering estrogen levels in premenopausal women with the use of luteinizing hormone-releasing hormone agonists, and in postmenopausal women by aromatase inhibitors that block estrogen biosynthesis in non-ovarian tissues. Large-scale international trials of adjuvant endocrine therapy over the last three or so decades have investigated and established these treatment approaches.17 Due to advances in treatment and early detection by screening, death rates in breast cancer have steadily decreased and 5-year survival currently exceeds 80% in most western countries.1 However, a significant number of women with HR-positive breast cancer remain at persistent risk of recurrence and death for the rest of their life.

With current standard of care adjuvant therapy, approximately 30% of women with HR-positive breast cancer initially diagnosed with early stage disease, experience distant relapse with metastases.18 A meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer reported that after 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5–20 years. The risk of distant recurrence was strongly correlated with the original tumor diameter and nodal (TN) status, with risks ranging from 10–41% depending on TN status and tumor grade. Remarkably, throughout this time, even among women with small, node-negative (T1N0), low-grade tumors, there was a risk of distant recurrence of approximately 10% during years 5–20. TN status was also a strong determinant of loco-regional recurrence, although not of contralateral disease.19 Despite progress in early detection and therapeutic options, unresectable or metastatic breast cancer remains one of the leading causes of cancer-related suffering and mortality. Although patient survival has improved over the past two decades, metastatic breast cancer is still incurable with the currently established treatment modalities.

Currently available evidence and clinical practice guidelines support endocrine therapy as the primary treatment approach for most patients with HR-positive metastatic breast cancer,20–23 until more rapidly progressive disease favors a switch to chemotherapy.24 However, this treatment strategy increasingly requires distinct clinical judgement, as the selection of treatment options continues to expand to include additional endocrine agents, alone or combined with targeted molecular agents; chemotherapy; and other molecularly-targeted approaches necessitating clinically useful metrics, alone or in combination, with proven biomarkers to select among the other treatment alternatives.25 Up to 50% of patients with HR-positive metastatic breast cancer develop resistance to the endocrine therapy.26 Overcoming de novo or secondary resistance in breast cancer remains critical to further enhancing the benefit of existing endocrine therapies.27 Improving clinical response rates to endocrine therapy and prolonging the duration of those responses while maintaining quality of life has been an important clinical research goal in the ER-positive metastatic breast cancer space. Fundamental to all research approaches has been an understanding of the various biological mechanisms responsible for the development of endocrine resistance together with preclinical evidence that manipulating specific signaling pathways with the use of targeted therapeutics can enhance or restore endocrine sensitivity, and thus improve the efficacy of current endocrine treatment.28 Co-targeting the ER, together with various key intracellular proliferation and cell survival signaling pathways, has been explored as a strategy.

Why does endocrine therapy lead to metabolic dysfunction and bone loss, and how common is it in women treated for breast cancer?

Estrogens are sex steroids that not only play a key role in reproduction, but are required for the normal functioning of numerous central and peripheral tissues.5 Early preclinical studies demonstrated that removal of estrogen, by knocking out the aromatase gene or following ovariectomy, or knockout of ER, leads to weight gain, metabolic syndrome, and decreased bone mineral density (BMD).29–31 This is also common in women who experience a drop in estrogen levels during the menopausal transition.32,33 The use of endocrine therapy can mimic a state of estrogen deficiency and further exacerbate the endocrine impacts of menopause. Studies have demonstrated that tamoxifen use was associated with a 24% higher risk of diabetes in Canadian breast cancer survivors aged ≥65 years,34 and a 31% higher risk in Taiwanese women aged >20 with early breast cancer.35 Recent observational data in a study of Israeli postmenopausal women with early breast cancer suggested that using an aromatase inhibitor was associated with a fourfold increased risk of diabetes compared to no endocrine treatment. In the same study, tamoxifen use doubled the risk of diabetes compared to no endocrine treatment.36 Importantly, the women in these studies were followed for 6–12 years. This association was not necessarily evident in limited duration observational studies of <2 years.37 In light of this evidence, and considering that two-thirds of women with breast cancer in the USA are overweight and obese, with higher rates of insulin resistance and diabetes, there is a risk that endocrine therapy will cause progression to diabetes in pre-diabetics or affect the management of women who have already been diagnosed with diabetes.38

There is also strong evidence for a link between endocrine therapy and the risk of skeletal deterioration and fracture. Women with breast cancer are usually post-menopausal and thus have low BMD at baseline, even prior to starting treatment. In the Women’s Health Initiative study, breast cancer survivors had a 15% increased risk of fractures compared to women who were cancer-free.39 In the skeleton, tamoxifen and aromatase inhibitors have quite different effects. The SERM, tamoxifen, is a partial estrogen receptor agonist in the bone, thus it promotes bone loss in premenopausal women, whereas it mitigates bone loss in postmenopausal women.40,41 In a major breast cancer prevention trial in high-risk postmenopausal women, tamoxifen use after 5 years reduced the risk of osteoporotic fractures by 32% compared to placebo.42 In contrast, tamoxifen decreases BMD in premenopausal women, even if they maintain regular menstrual cycles.41 In postmenopausal women, adjuvant aromatase inhibitors are superior to tamoxifen and widely used. In those women, aromatase inhibitors accelerate bone loss and increase fracture risk by at least ~10%43–46 and up to 20% after 5 years of treatment.47 Longer duration of aromatase-inhibitor therapy is associated with higher increases in the risk of fracture, at 14% versus 9% in those treated for 10 years versus 5 years, respectively.47 The incidence of fragility fractures from osteoporosis in women treated with aromatase inhibitors was shown to be 18–20% after 5 years of treatment in the ABCSG-18 clinical trial that used fracture endpoints.48

Are there consequences of diabetes and bone loss on risk of recurrence?

Women with diabetes have a 15–20% increased risk of developing breast cancer compared to women without diabetes.49 The literature is scarce regarding the link of diabetes and specific pathologic characteristics, although reported data suggest that women with diabetes are more likely to be diagnosed with advanced stage and more aggressive breast cancer.50–54 Studies have also indicated that mortality after breast cancer diagnosis is 30–60% higher among women with diabetes, including after correction for tumor stage;53,55–58 although it remains unclear whether this is driven by worse breast cancer prognosis or by competing risks such as cardiovascular disease. Self-reported diabetes was associated with more than a two-fold increase in both breast cancer events and all-cause mortality.59 Research has shown that chronic hyperglycemia is significantly associated with reduced overall survival in survivors of early breast cancer.56 Clinical studies suggest that the biologic effects of both inflammation and obesity could promote cancer and the hyperinsulinemia associated with these conditions increases cell proliferation and survival.60–62 Results have been inconsistent from studies investigating the association between breast cancer-specific mortality and diabetes.63–65

Experimentally, a number of factors have been shown to have effects on cancer cells that explain, at least in part, the relationship between diabetes and breast cancer. Candidates include insulin and glucose, as well as inflammatory mediators and estrogens produced locally in the breast adipose tissue.6,66–68 Some tumors rely heavily on glucose as a source of energy and, as a result, display enhanced glucose uptake and metabolism.69 This is the basis of 18F-FDG positron emission tomography, whereby a non-metabolizable glucose tracer is used to image cancer metastases.70 Hyperinsulinemia has also been shown to be a key driver of the diabetes–breast cancer link via stimulation of PI3K/Akt signaling in cancer cells.

The impact of osteoporosis on breast cancer recurrence is not as well defined. A cohort study using electronic medical records of 9,104 patients with breast cancer and 14,020 patients with precancer osteoporosis, showed that cancer osteoporosis was not associated with a risk of bone metastasis, but untreated osteoporosis was associated with accelerated progression of bone metastasis when it occurred.71 Ultimately osteoporotic bone loss and bone metastasis share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts.

How are endocrine therapy-related endocrinopathies managed?

There are no data specifically related to the management of diabetes in women with breast cancer on endocrine therapies. The recommendations regarding decreasing the risk of development of diabetes, as well as managing diabetes in order to prevent long term microvascular and macrovascular complications, are currently the same for women with breast cancer on endocrine therapy as in the general population.

In people with prediabetes, lifestyle changes have been shown to reduce the risk of progression to diabetes by almost 70%. Therefore, educating and motivating patients with breast cancer, and survivors, to adopt healthy lifestyle modifications is imperative. Those includes smoking cessation, diet modifications (diet high in vegetables, fruits, whole grains, and legumes but low in saturated fats and simple carbohydrates), and exercise (at least 150 minutes of moderate or 75 minutes of vigorous aerobic exercise per week, including strength training exercises at least 2 days per week). Exercise partially reversed fat mass accumulation and lean mass loss in premenopausal women on tamoxifen plus ovarian suppression.72

Pharmacologic treatment of diabetes in women with breast cancer is based on current guidelines for treating the general population of people with diabetes. The first-line agent, and most widely-used agent, in type 2 diabetes is metformin given its strong efficacy in reducing glycated hemoglobin (HbA1c) and maintaining glycemic control; other concurrent beneficial effects include weight loss, reduction of cardiovascular risk, reduction of risk of death, low cost, and good tolerance with minimal adverse events.73 Beyond metformin, other agents utilized for glycemic control with associated weight loss, cardiovascular risk reduction, and reduction of risk of chronic kidney disease are sodium–glucose cotransporter 2 inhibitors (SGLT2 inhibitors), or glucagon-like peptide 1 receptor agonists (GLP1), ideally in combination with metformin.74

All women receiving treatment for breast cancer should be evaluated for their risk of fracture at the onset of therapy, particularly because osteoporosis may be a pre-existing condition. A thorough history and a dual-energy X-ray absorptiometry (DXA) scan should be performed. Universal lifestyle measures that mitigate the rate of bone loss are highly important and include regular weight bearing, resistance, muscle strengthening, and balance exercises; and smoking cessation and diet rich in calcium, natural antioxidants, protein, without excess red meat, caffeine, colored carbonated beverages or alcohol. Weight-bearing and resistance exercise has been shown to limit bone loss in postmenopausal women with breast cancer, although fracture risk reduction has not been demonstrated.47 The foundation of maintaining bone health includes intake of adequate calcium (1,000–1,200 mg daily, preferably from food sources; however, supplements may be added) and vitamin D ~800–1,000 units/d for a 25-OH vitamin D level above 30 ng/mL, as is recommended for fall and fracture prevention in the general osteoporosis population.75 Adequate calcium and vitamin D intake decreases the risk of hypocalcemia and maintains bone mineralization in the setting of antiresorptive therapies.

In 2017, multiple societies issued a combined position statement to address this issue.47 Medications that reduce bone resorption such as bisphosphonates and denosumab are widely used and indicated in these women as the only effective means to actually reduce fracture risk. Treatment with either a bisphosphonate or denosumab is recommended for the duration of treatment with aromatase inhibitors.47,76 In postmenopausal women with breast cancer receiving aromatase-inhibitor therapy, oral bisphosphonates (alendronate, ibandronate, and risedronate) when used for up to 5 years are associated with increases in BMD and reduction in fracture risk.47,76 In women with taking anastrozole, BMD increased by 16% after 3 years of alendronate (compared to 5% loss on placebo in osteoporosis)77 and by 2% (versus almost 2% loss on placebo) after 2 years of risedronate.78

The AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial investigated the addition of zoledronic acid to standard adjuvant treatments in patients with early breast cancer, over a treatment period of 5 years. The results showed that the addition of zoledronic acid significantly lowered overall fracture rate by 6.2% versus 8.3% in the control group.79 In the Z-FAST (Zometa-Femara Adjuvant Synergy Trial) and ZO-FAST (Zometa-Femara Adjuvant Synergy Trial) studies, postmenopausal women on adjuvant aromatase-inhibitor therapy were randomized to either up-front use of zoledronic acid (4 mg every 6 months) or delayed use of the zoledronic acid regimen.46,79 Both studies found that those treated with zoledronic acid up-front group had increases in BMD, but fracture rates were not statistically different across the treatment arms. Similar data are available from the E-ZO-FAST and ABSCG-12 (Austrian Breast Cancer Study Group) trials.80,81

Denosumab is approved for women on aromatase inhibitors at high-risk for osteoporotic fracture. The ABCSG-18 trial of denosumab versus placebo, demonstrated that time to first clinical fracture was decreased in the denosumab-treated group regardless of baseline BMD or age. As expected, denosumab was associated with increasing BMD at all skeletal sites.48 In postmenopausal women on aromatase inhibitors, denosumab increased bone mass by 6–8% compared with placebo,45 and reduced the risk of clinical fractures (hazard ratio [HR] 0.50), vertebral, and non-vertebral fractures over 3 years of treatment irrespective of baseline T score and age.41 BMD should also be assessed in premenopausal women with amenorrhea associated with treatment for breast cancer, and treatment should be offered if their BMD is low for their age or they have a rapid rate of bone loss (5–10% annually).82 There is currently limited evidence to suggest recommendation of bone density measurement in premenopausal women on Tamoxifen who are still menstruating and have not had a fragility fracture.

Can the treatment of endocrinopathies reduce recurrence overall?

Metformin and GLP1 analogs may have promising antitumor effects in women with breast cancer either independently, or possibly due to maintenance of glycemic control.83,84 Metformin, an oral biguanide commonly used to treat type 2 diabetes, has been associated with reduced incidence of breast cancer as well as improved breast cancer outcomes in observational studies largely conducted in individuals with diabetes.85,86 Preclinical data suggest that metformin might act synergistically with certain chemotherapy;87,88 however, recent phase II randomized studies failed to provide evidence in support of an anticancer activity of metformin when added to standard chemotherapy in women without diabetes and with metastatic breast cancer.87,89 In vivo evidence from window studies shows an antiproliferative effect of metformin in breast cancer.90,91 A neoadjuvant “window of opportunity” study of metformin in women without diabetes with operable breast cancer showed that short-term preoperative metformin was well tolerated and resulted in clinical and cellular changes consistent with beneficial anti-cancer effects; evaluation of the clinical relevance of these findings in adequately powered clinical trials using clinical endpoints such as survival is needed.91,92 Other ongoing studies are investigating the role of metformin in the adjuvant/neoadjuvant early-stage disease setting, including the M.32 large multinational phase III trial (ClinicalTrials.Gov Identifier. NCT01101438). Meta-analyses have examined the role of metformin in the primary prevention of cancer, demonstrating that it significantly reduces overall cancer incidence, but the findings were inconsistent for tumor types.93,94

The mechanism behind the protective effects of metformin has been extensively studied, yet remains incompletely understood. A number of studies have demonstrated effects of metformin on isolated breast cancer cells at micromolar doses.95 Although there is still debate regarding transport of the drug into/out of cancer cells that would support a direct effect of metformin, these doses exceed those achievable in women, largely due to life-threatening toxicities.96 Additional studies point towards important effects of lowering systemic glucose and insulin levels, as well as estrogen production in the breast adipose.92,97,98 Most studies implicate activation of the metabolic sensor AMP-activated protein kinase (AMPK).

Interestingly, a systematic review and meta-analysis involving nearly 1 million women, that included many of the studies mentioned above, demonstrated that the use of bisphosphonates for >1 year was associated with a 12% decreased risk of primary breast cancer.99 Similar findings were observed for denosumab where use was associated with a 13% decreased risk of developing breast cancer.100 In women with early breast cancer, bisphosphonates were associated with a 14% reduction in the risk of bone metastases.101 The role of bone-targeted agents in the adjuvant treatment of early breast cancer has been debated for decades. In 2015, the Early Breast Cancer Trialists Collaborative Group (EBCTCG)102 conducted a meta-analysis including individual data from 18,766 women from 26 clinical trials including the ABCSG-12,77 AZURE.75 This meta-analysis provided the strongest evidence to date supporting the use of these agents in postmenopausal women with early-stage breast cancer. The meta-analysis demonstrated specifically in postmenopausal patients that the use of adjuvant bisphosphonates resulted in significant improvements in bone recurrence (6.6% versus 8.8%; p=0.0002), breast cancer mortality (14.7% versus 18.0%; p=0.002), or all-cause mortality (21.1% versus 23.5%; p=0.005) except distant recurrence outside of bone (12.1% versus 13.6%; p=0.10) was not statistically significant. Significantly, subgroup analyses by menopausal status showed a dramatic benefit in postmenopausal women (n= 11,767) and there was no benefit in the premenopausal women (n= 6,171).98

The beneficial effects of bone-targeted agents were reported with each bisphosphonate class, treatment schedule and dose, and were not associated with any particular tumor characteristic (HR status, nodal status, tumor grade); or whether the patient received concomitant chemotherapy.102 In the EBCTCG analysis, the data examining bisphosphonates in premenopausal women in an induced menopausal through ovarian suppression were provided by the ACCSG-12 phase III randomized trial of zoledronic acid.103 The mechanism underlying this differential benefit is not clear; however, evidence is accumulating, indicating that reproductive hormones and bisphosphonates can have similar effects on paracrine and cellular components of the bone metastatic niche.

Most studies included in the Oxford meta-analysis were randomized trials examining the use of bisphosphonate for 2–5 years duration.102 The Success A trial recently reported no benefit for extending the use of intravenous zoledronic acid from 2–5 years.104 SWOG S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer and reported no evidence of differences in efficacy by type of bisphosphonate either in the intent to treat analysis or based on age and menopausal status.105

As a result of this compelling evidence, bisphosphonates are becoming a part of a standard of care in the adjuvant treatment for early breast cancer. The American Society of Clinical Oncology and Cancer Care Ontario convened a working group of experts to develop evidence-based recommendations76 to guide the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Results from the ABCSG-18,106 a randomized trial of denosumab a RANK ligand inhibitor in postmenopausal women with HR-positive breast cancer, showed that use of denosumab as an adjuvant to aromatase-inhibitor therapy significantly reduced clinical fractures and also improved disease-free survival outcomes (HR 0.82 [95% CI 0.69–0.98], Cox p=0.0260). Furthermore, the addition of adjuvant denosumab to the regimen did not increase toxic effects—most notably, there were no documented cases of osteonecrosis of the jaw. Shortly after, the D-Care study challenged the perspective for practice changing, establishing denosumab as an alternative to bisphosphonates since it failed to show benefit in bone metastases-free survival and disease-free survival also in the expense of higher toxicity due to the intense schedule.107

Future directions

There is now evidence to support a link between the use on endocrine therapy for the treatment of breast cancer and the development of endocrinopathies. Proper management of these side effects may, in fact, contribute to decreasing the risk of cancer recurrence. Should we therefore consider endocrine consequences of breast cancer therapies and preemptively treat with drugs like metformin or bisphosphonates? Food for thought.

Article Information:

Kristy A Brown, Eleni Andreopoulou, and Panagiota Andreopoulou have no conflicts of interest to declare in relation to this article.

Compliance With Ethics

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Kristy A Brown, 1300 York Avenue, Room E-804, New York, NY 10065, USA. E:


This work was supported by the Anne Moore Breast Cancer Research Fund, the Kat’s Ribbon of Hope and NIH R01 CA215797.


This article is freely accessible at © Touch Medical Media 2020.




  1. American Cancer Societ. Breast Cancer Facts & Figures 2017- 2018. Available at: research/cancer-facts-and-statistics/breast-cancer-facts-and- figures/breast-cancer-facts-and-figures-2017-2018.pdf (accessed January 14, 2020).
  2. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused J Clin Oncol. 2019:37;423–38.
  3. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309.
  4. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016;34:1689–701.
  5. Santen RJ, Brodie H, Simpson ER, et al. History of aromatase: saga of an important biological mediator and therapeutic Endocr Rev. 2019;30:343–75.
  6. Bhardwaj P, Au CC, Benito-Martin A, et al. Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019;189:161–70.
  7. Lønning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22:503–14.
  8. Arao Y, Korach Transactivation function-1-mediated partial agonist activity of selective estrogen receptor modulator requires homo-dimerization of the estrogen receptor alpha ligand binding domain. Int J Mol Sci. 2019;20: pii: E3718.
  9. Sasaki LMP, Andrade KRC, Figueiredo A, et al. Factors associated with malignancy in hysteroscopically resected endometrial polyps: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2018;25:777–85.
  10. Gombos, A. Selective oestrogen receptor degraders in breast cancer: a review and perspectives. Curr Opin Oncol. 2019;31:424–9.
  11. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 J Natl Cancer Inst. 2014;106: pii: dju055.
  12. Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based NPJ Breast Cancer. 2016;2:16017.
  13. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- Ann Oncol. 2015;26 (Suppl 5):v8–30.
  14. Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working J Natl Cancer Inst. 2011;103:1656–64.
  15. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies– improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–46.
  16. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised Lancet. 2005;365:1687–717.
  17. Early Breast Cancer Trialists’ Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient- level meta-analysis of randomised trials. 2011;378:771–84.
  18. Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7:304–20.
  19. Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 N Engl J Med. 2017;377:1836–46.
  20. Wilcken N, Hornbuckle J, Ghersi Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;CD002747.
  21. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014;25:1871–88.
  22. Dodwell D, Wardley A, Johnston Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast. 2006;15:584–94.
  23. Barrios C, Forbes JF, Jonat W, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012;23:1378–86.
  24. Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007;18:215–25.
  25. Arnedos M, Vicier C, Loi S, et al. Precision medicine for metastatic breast cancer–limitations and solutions. Nat Rev Clin Oncol. 2015;12:693–704.
  26. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.
  27. Ali S, Coombes Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101–12.
  28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
  29. Oz OK, Hirasawa G, Lawson J, et al. Bone phenotype of the aromatase deficient mouse. J Steroid Biochem Mol Biol. 2001;79:49–59.
  30. Jones ME, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice accumulate excess adipose tissue. J Steroid Biochem Mol Biol. 2001;79:3–9.
  31. Pallier E, Aubert R, Lemonnier Effect of diet and ovariectomy on adipose tissue cellularity in mice. Reprod Nutr Dev. 1980;20:631–6.
  32. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr 2017;38:173–88.
  33. Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180:41–50.
  34. Lipscombe LL, Fischer HD, Yun L, et al. Association between tamoxifen treatment and diabetes: a population-based Cancer. 2012;118:2615–22.
  35. Sun LM, Chen HJ, Liang JA et al. Association of tamoxifen use and increased diabetes among Asian women diagnosed with breast cancer. Br J Cancer. 2014;111:1836–42.
  36. Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Diabetes after hormone therapy in breast cancer survivors: a case-cohort J Clin Oncol. 2018;36:2061–9.
  37. Santorelli ML, Hirshfield KM, Steinberg MB, et al. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women. Ann Epidemiol. 2016;26:436–40.
  38. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34:611–35.
  39. Chen Z, Maricic M, Aragaki AK, et al. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women’s Health Initiative. Osteoporos Int. 2009;20:527–36.
  40. Grossmann M, Ramchand SK, Milat F, et al. Assessment and management of bone health in women with oestrogen receptor- positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Clin Endocrinol (Oxf). 2018;89:280–96.
  41. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84.
  42. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 J Natl Cancer Inst. 2005;97:1652–62.
  43. Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011;47:683–9.
  44. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25:820–8.
  45. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–82.
  46. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. 2012;118:1192–201.
  47. Hadji P, Aapro MS, Body JJ, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1–12.
  48. Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double- blind, placebo-controlled trial. 2015;386:433–43.
  49. Liao S, Li J, Wei W, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 2011;12:1061–5.
  50. Wolf I, Sadetzki S, Gluck I, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006;42:1077–82.
  51. Overbeek JA, van Herk-Sukel MPP, Vissers PAJ, et al. Type 2 diabetes, but not insulin (analog) treatment, is associated with more advanced stages of breast cancer: a national linkage of cancer and pharmacy registries. Diabetes Care. 2019;42:434–42.
  52. He DE, Bai JW, Liu J, et al. Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. Mol Clin Oncol. 2015;3:607–12.
  53. Bronsveld HK, Jensen V, Vahl P, et al. Diabetes and breast cancer subtypes. PLoS One. 2017;12:e0170084.
  54. Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based Breast Cancer Res Treat. 2015;150:613–20.
  55. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011;29:40–6.
  56. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast J Clin Oncol. 2011;29:54–60.
  57. Redaniel MT, Jeffreys M, May MT, et al. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control. 2012;23:1785–95.
  58. Schrauder MG, Fasching PA, Häberle L, et al. Diabetes and prognosis in a breast cancer cohort. J Cancer Res Clin Oncol. 2011;137:975–83.
  59. Patterson RE, Flatt SW, Saquib N, et al. Medical comorbidities predict mortality in women with a history of early stage breast cancer. Breast Cancer Res Treat. 2010;122:859–65.
  60. Pasanisi P, Berrino F, De Petris M, et al. Metabolic syndrome as a prognostic factor for breast cancer recurrences. International journal of cancer. Int J Cancer. 2006;119:236–8.
  61. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort J Clin Oncol. 2002;20:42–51.
  62. Borugian MJ, Sheps SB, Kim-Sing C, et al. Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158:963–8.
  63. Zhou XH, Qiao Q, Zethelius B, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867–76.
  64. Fleming ST, Rastogi A, Dmitrienko A, Johnson A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999;37:601–14.
  65. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. 2010;375:2215–22.
  66. Kang C, LeRoith D, Gallagher Diabetes, obesity, and breast cancer. Endocrinology. 2018;159:3801–12.
  67. Zahid H, Subbaramaiah K, Iyengar NM et al. Leptin regulation of the p53-HIF1alpha/PKM2-aromatase axis in breast adipose stromal cells: a novel mechanism for the obesity-breast cancer link. Int J Obes (Lond). 2018;42:711–20.
  68. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast Cancer Prev Res (Phila). 2011;4:1021–9.
  69. Vander Heiden MG, Cantley LC, Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
  70. Chakraborty D, Basu S, Ulaner GA, et al. Diagnostic role of fluorodeoxyglucose PET in breast cancer: a history to current application. PET Clin. 2018;13:355–61.
  71. Chen HM, Chen FP, Yang KC, Yuan Association of bone metastasis with early-stage breast cancer in women with and without precancer osteoporosis according to osteoporosis therapy status. JAMA Netw Open. 2019;2:e190429.
  72. Hojan K, Molinska-Glura M, Milecki Physical activity and body composition, body physique, and quality of life in premenopausal breast cancer patients during endocrine therapy–a feasibility study. Acta Oncol. 2013;52:319–26.
  73. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 20085;359:1577–89.
  74. American Diabetes Association. Standards of medical care in diabetes-2019 abridged for primary care providers. Clin 2019;37:11–34.
  75. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151–4.
  76. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:2062–81.
  77. Lomax AJ, Yee Yap S, White K, et al. Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN J Bone Oncol. 2013;2:145–53.
  78. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol. 2010;28:967–75.
  79. Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398–405.
  80. Llombart A, Frassoldati A, Paija O, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer.2012;12:40–8.
  81. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840–9.
  82. Hadji P, Gnant M, Body JJ, et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev. 2012;38:798–806.
  83. Chen L, Chubak J, Boudreau DM, et al. Diabetes treatments and risks of adverse breast cancer outcomes among early-stage breast cancer patients: A SEER-Medicare analysis. Cancer Res. 2017;77:6033–41.
  84. Iwaya C, Nomiyama T, Komatsu S, et al. Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kappaB activation. Endocrinology. 2017;158:4218–32.
  85. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic BMJ. 2005;330:1304–5.
  86. Morales DR, Morris Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29.
  87. Pimentel I, Lohmann AE, Ennis M, et al. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast. 2019;48:17–23.
  88. Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral Clin Cancer Res. 2011;17:3993–4005.
  89. Nanni O, Amadori D, De Censi A, et al. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast Cancer Res Treat. 2019;174:433–42.
  90. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128:783–94.
  91. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant Breast Cancer Res Treat. 2012;135:821–30.
  92. Dowling RJ, Niraula S, Chang MC, et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant Breast Cancer Res. 2015;17:32.
  93. Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37:207–18.
  94. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta- PLoS One. 2012;7:e33411.
  95. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–73.
  96. Kuan IHS, Savage RL, Duffull SB, et al. The association between metformin therapy and lactic Drug Saf. 2019;42:1449–69.
  97. Goodwin PJ, Pritchard KI, Ennis M, et al. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008;8:501–5.
  98. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat. 2010;123:591–6.
  99. Liu Y, Zhang X, Sun H, et al. Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women. Clin Epidemiol. 2019;11:593–603.
  100. Giannakeas V, Cadarette SM, Ban JK et al. Denosumab and breast cancer risk in postmenopausal women: a population-based cohort Br J Cancer. 2018;119:1421–7.
  101. O’Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.
  102. Early Breast Cancer Trialists’ Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61.
  103. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26:313–20.
  104. Janni W, Friedl TWP, Fehm T, et al. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS1-06.
  105. Gralow JR, Barlow WE, Paterson AHG, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst. 2019; pii: djz215. [Epub ahead of print]
  106. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 Lancet Oncol. 2019;20:339–51.
  107. Steger GG, Bartsch R. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol. 2011;3:233–43.

Further Resources

Share this Article
Related Content In Breast Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72